Ligand Pharmaceuticals (LGND) Cost of Revenue (2011 - 2026)

Ligand Pharmaceuticals has disclosed Cost of Revenue across 16 years of filings, most recently posting $3.3 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $3.3 million, down 32.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.0 million (down 0.52% YoY), and the FY2025 annual result was $14.5 million, up 31.38% from the prior year.
• Cost of Revenue came in at $3.3 million for Q1 2026 at Ligand Pharmaceuticals, up from $3.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $21.6 million in Q4 2022 to a low of $1.6 million in Q4 2023.
• The 5-year median for Cost of Revenue is $3.3 million (2026), against an average of $5.4 million.
• Across the five-year window, Cost of Revenue jumped 80.36% in 2022 and sank 92.41% in 2023, its largest moves.
• Ligand Pharmaceuticals' Cost of Revenue stood at $21.6 million in 2022, then tumbled by 92.41% to $1.6 million in 2023, then soared by 72.88% to $2.8 million in 2024, then advanced by 5.46% to $3.0 million in 2025, then gained by 9.39% to $3.3 million in 2026.
• The last three Cost of Revenue figures came in at $3.3 million (Q1 2026), $3.0 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.